1207 Merck VelosBio ADC
BioCentury

Product Development

ADC and ROR1 momentum grows with ASH data behind Merck, VelosBio deal

Dec 8, 2020 | 2:06 AM GMT

ASH data presented by VelosBio — which drove the latest in a string of high wattage ADC deals — is building confidence in a target valued for its potential in both solid and hematological

Read the full 581 word article

How to gain access

Continue reading with a
two-week free trial.